Evaluation of thyroid dysfunction in chronic obstructive pulmonary disease.

Gupta Madhuri¹, Vardey SK¹, Joshi Nalin², Dixit R³

¹Department of Biochemistry, SMS Medical College and hospital, Jaipur, Rajasthan, India
²Institute of Respiratory Diseases, SMS Medical College and hospital, Jaipur, Rajasthan, India.
³TB and Chest Hospital, JLN Medical College, Ajmer, Rajasthan, India

Abstract

Thyroid dysfunction is associated with chronic obstructive pulmonary disease depending upon severity of disease. The aim of this study was to evaluate thyroid function impairment among stable and acute exacerbation COPD patients with age matched healthy controls and correlation of thyroid function tests with pulmonary function test and arterial blood gas analysis. 60 {30 stable (group1) and 30 exacerbation (group2)} COPD patients and 30 age matched healthy controls (group3) were studied. There was a significant difference with respect to BMI, mean serum FT₃ in between group 1&2; group 2&3 and group 1&3. Mean serum TSH was within normal limits but had lower values than controls. FT4 was within normal limits. It had no significant difference between all groups. Mean serum FT3 was negatively correlated with bicarbonate levels whereas FT4 was negatively correlated to Hb levels. No correlation was found in between Pulmonary Function Test and ABG analysis with thyroid function impairment. In conclusion among all groups of COPD patients, impaired thyroid function is associated with respiratory workload, as thyroid hormones regulate the metabolic rate and in exacerbation phase due to critical illness thyroid dysfunction reflects non-thyroidal illness syndrome.

Keywords: COPD, thyroid hormones, acute exacerbation, pulmonary function test, arterial blood gases

Introduction

Chronic obstructive pulmonary disease (COPD) is a major cause of chronic morbidity and mortality throughout the world. The Global Burden of Disease Study has projected that COPD which ranked sixth as the cause of death in 1990, will become the third leading cause of death worldwide by 2020 [1]. COPD is no longer considered to affect only the lungs and airways but also the rest of the body. The systemic manifestations of COPD include a number of endocrine disorders, such as those involving the pituitary, the thyroid etc. The thyroid hormone regulates the metabolism of proteins, lipids and carbohydrates, and controls the activity of membrane-bound enzymes [2, 3]. The thyroid hormone enhances mitochondrial oxidation, and thus, augments metabolic rate [4]. This effect on metabolic rate is probably responsible for the association between the thyroid hormone and respiratory drive [5]. Limited data on the prevalence of thyroid diseases among patients with COPD are available [6, 7] yet, several characteristics of patients with COPD could potentially increase their likelihood of developing hypothyroidism and hyperthyroidism. Also the severity of airway obstruction in these patients affects the rate of survival [8] and is associated with impairment of thyroid gland function [9]. So there might be a possibility of differences in hormone levels during stable and exacerbation phases in comparison to healthy controls.

In this study, we evaluated abnormalities and the correlation of thyroid hormone concentration, arterial blood gas analysis (ABG) and pulmonary function test (PFT) among stable and exacerbation COPD patients with comparison to age-matched healthy controls.

Material and Methods

Subjects

The study group comprised of 60 COPD patients and 30 control subjects. In patient group they were subdivided again under stable (30) and acute exacerbation phases (30). The patients with COPD were diagnosed according to the Global Initiative for Chronic Obstructive Lung Disease Criteria [1], by the respiratory Physician.30 patients had been clinically stable for at least 3 months and 30 had clinical signs of COPD exacerbation. Stable COPD patients had been receiving inhaled bronchodilator therapy.
in the form of long-acting β2-agonists and/or anticholinergic agents. Severe/very severe COPD patients were on inhaled corticosteroids. The patients were not receiving iodine-containing drugs. Patients diagnosed with endocrinological disorders, on systemic steroid therapy or displaying an infected profile (fever, leucocytosis, consolidation area on performed chest X ray) and using long term oxygen therapy were excluded from the study. From total 60 patients 32 were ex smokers, 22 were current smokers and 6 were nonsmokers.

The control group comprises 30 (20 male and 10 females) age matched healthy individuals; all were non smokers, not on any medication, whose written consents were obtained from them. The study was approved by the institutional ethics committee and written consent was also obtained in each case.

Study design
A clinical history was obtained and a physical examination performed on the patients who attended the institute of respiratory diseases, SMS medical college and hospital, Jaipur. After an overnight fast, height and nude weight were measured in all subjects and body mass index (BMI) was calculated. Arterial blood gas measurements were taken on the same day with the PFT. PFT was performed using SpiroAnalyser HELIOS 400 according to acceptable manoeuvre. Arterial blood samples were drawn while the subjects were breathing room air and analyzed with a blood gas analyzer immediately (STAT PRO PHOX Plus L, Nova Biomedical). Serum thyroid hormones were measured in 5 ml venous blood during morning fasting. Serum levels of free triiodothyronine (FT3), free thyroxine (FT4) and thyroid-stimulating hormone (TSH) were determined by using the commercial IMMULITE kits, which are solid-phase, two-site chemiluminescent immunometric assays (IMMULITE, SIEMENS Healthcare Diagnostics).

Statistical Analysis
Results were expressed as the mean±SD. Statistical analysis was performed by Student’s t test for comparing 2 experimental groups and control group. Pearson’s Correlation analysis was also performed. p value < 0.05 was considered significant.

Results
The characteristics of all patients and healthy controls were shown in table -1 and table-2. No significant difference was seen between the study group (clinically stable; group 1 and exacerbation; group 2) patients and controls (group 3) with respect to age, gender and smoking status (table1). BMI was found to be significantly different in group1 vs. group3 and group 2 vs. group 3. All patients with A/E COPD suffered from severe to very severe airway obstruction with an FEV1 in percentage predicted of 36.47 ± 10.37% as compared to stable COPD patients (66.97 ± 23.82) (p < .001). All COPD patients of group 1 and group 2 were hypoxemic with significant difference in pO2 among healthy vs. group1 and group 2 (92.26 ± 1.72 vs. 75.52 ± 8.79 and 61.76 ±13.06) respectively. Group2 patients were hypercapnics as comparable to group1 and group3 (51.01 ± 15.75 vs. 42.21 ± 5.04 and 38.41 ± 1.84) respectively (p< 0.01).

The mean serum FT3 levels were lower among exacerbation COPD patients whereas among group1 and 3 had lower mean values but within normal limits (1.55±0.36 vs. 2.62±1.04 and 3.22±0.70) respectively. Thus there was a significant difference of mean serum FT3 levels in between group 1 vs. 2, group 1 vs. 3, group 2 vs. 3 (p < .001). Serum FT4 levels were within normal limits in all three groups but towards the lower limit in group 2. There was no significant difference in mean levels of serum FT4 (P > 0.05). Among all groups serum TSH level was also within normal limits with significant difference in mean levels of TSH in between group 2 and 3 (p < 0.05). During the correlations between various variables in a group, in exacerbation COPD patients significant negative correlation was observed between FT3 and HCO3 levels (r= -0.428; p=0.018). Similarly Hb levels also showed significant negative correlation with serum FT3, (r= -0.437; p = 0.01). There was no correlation between FT3, FT4 or TSH and pO2, pCO2, SO2 and PFT.

Table 1. Characteristics of patients and Control Cases

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Stable</th>
<th>Exacerbation</th>
<th>Controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, (years)</td>
<td>63.27 ± 8.41</td>
<td>64.30 ± 7.91</td>
<td>65.50 ± 7.67</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>22/30</td>
<td>21/30</td>
<td>20/30</td>
</tr>
<tr>
<td>Female</td>
<td>8/30</td>
<td>9/30</td>
<td>10/30</td>
</tr>
<tr>
<td>Smoking</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>26/30</td>
<td>28/30</td>
<td>-</td>
</tr>
<tr>
<td>No</td>
<td>4/30</td>
<td>20/30</td>
<td>30/30</td>
</tr>
</tbody>
</table>

Biomed Res- India 2013 2013 Volume 24 Issue 1
TH concentration in chronic obstructive pulmonary disease

**Table 2.** BMI, Results of PFT and arterial blood gas analysis and concentrations of thyroid hormone (mean ± SD) in patients with stable, A/E COPD and controls.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Stable (Group-1)</th>
<th>Exacerbation (Group - 2)</th>
<th>Control (Group - 3)</th>
<th>P*</th>
<th>P**</th>
<th>P***</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMI (Kg/m²)</td>
<td>18.98 ± 3.24</td>
<td>17.65 ± 2.71</td>
<td>25.30 ± 4.36</td>
<td>0.000*</td>
<td>0.000*</td>
<td>0.0899</td>
</tr>
<tr>
<td>FVC(%predicted)</td>
<td>85.57 ± 18.11</td>
<td>54.97 ± 11.79</td>
<td>105.60 ± 13.50</td>
<td>0.000*</td>
<td>0.000*</td>
<td>0.000*</td>
</tr>
<tr>
<td>FEV1(%predicted)</td>
<td>66.97 ± 23.82</td>
<td>36.47 ± 10.37</td>
<td>113.33 ± 13.12</td>
<td>0.000*</td>
<td>0.000*</td>
<td>0.000*</td>
</tr>
<tr>
<td>FEV1/FVC (%)</td>
<td>76.59 ± 13.15</td>
<td>66.00 ± 9.97</td>
<td>107.57 ± 4.64</td>
<td>0.000*</td>
<td>0.000*</td>
<td>0.009*</td>
</tr>
<tr>
<td>PH</td>
<td>7.40 ± 0.03</td>
<td>7.40 ± 0.06</td>
<td>7.40 ± 0.03</td>
<td>0.6304</td>
<td>0.8204</td>
<td>0.9278</td>
</tr>
<tr>
<td>pO₂ (mmHg)</td>
<td>75.52 ± 8.79</td>
<td>61.76 ± 13.06</td>
<td>92.26 ± 1.72</td>
<td>0.0000*</td>
<td>0.000*</td>
<td>0.000*</td>
</tr>
<tr>
<td>pCO₂ (mmHg)</td>
<td>42.21 ± 5.04</td>
<td>51.01 ± 15.75</td>
<td>38.41 ± 1.84</td>
<td>0.0004*</td>
<td>0.0001*</td>
<td>0.0062*</td>
</tr>
<tr>
<td>SO₂ (%)</td>
<td>93.23 ± 1.91</td>
<td>86.26 ± 7.61</td>
<td>93.43 ± 1.45</td>
<td>0.6444</td>
<td>0.0000*</td>
<td>0.000*</td>
</tr>
<tr>
<td>HCO₃, mmol/L</td>
<td>26.01 ± 2.79</td>
<td>31.77 ± 6.89</td>
<td>25.89 ± 1.61</td>
<td>0.8450</td>
<td>0.0001</td>
<td>0.0001*</td>
</tr>
<tr>
<td>Hct, %</td>
<td>49.96 ± 13.04</td>
<td>49.99 ± 8.57</td>
<td>40.83 ± 2.33</td>
<td>0.0007</td>
<td>0.0000</td>
<td>0.9922</td>
</tr>
<tr>
<td>Hb, (gm/dl)</td>
<td>12.55 ± 1.77</td>
<td>12.41 ± 1.38</td>
<td>13.06 ± 0.94</td>
<td>0.1673</td>
<td>0.0373</td>
<td>0.7340</td>
</tr>
<tr>
<td>tT₃, (pg/ml)</td>
<td>2.62 ± 1.04</td>
<td>1.55 ± 0.36</td>
<td>3.28 ± 0.70</td>
<td>0.0056*</td>
<td>0.0000*</td>
<td>0.0000*</td>
</tr>
<tr>
<td>tT₄, (ng/ml)</td>
<td>1.09 ± 0.38</td>
<td>1.06 ± 0.21</td>
<td>1.14 ± 0.21</td>
<td>0.5100</td>
<td>0.1297</td>
<td>0.6970</td>
</tr>
<tr>
<td>TSH, (µIU/ml)</td>
<td>2.30 ± 1.29</td>
<td>2.08 ± 1.31</td>
<td>2.64 ± 0.87</td>
<td>0.2506</td>
<td>0.0501</td>
<td>0.5115</td>
</tr>
</tbody>
</table>

★ p < 0.05=significant and  < 0.01 & <0.001=HS(Highly Significant)

p > 0.05=NS(Non-Significant),

*obtained by comparison of stable COPD patients and controls,

**obtained by comparison of exacerbation COPD and controls,

***obtained by comparison of stable and exacerbation COPD.

**Discussion**

Impaired thyroid function can present as subclinical hypothyroidism, overt hypothyroidism and nonthyroidal illness syndrome. Of these, the nonthyroidal illness syndrome is the most common in COPD [6]. Patients with nonthyroidal illness syndrome have decreased levels of the biologically active hormone T₃ and normal or decreased levels of the prohormone T₄ [10]. Serum levels of the TSH are usually normal, though they can be low in the most severely ill patients [11]. The presence of thyroid dysfunction may vary according to the phases of COPD. Thus we investigated the thyroid functions among stable and A/E phases. We found that among A/E COPD patients as compared to stable, this syndrome was more marked as mean FT3 values suggests and mean TSH values were also comparable in between group 2 and 3. Pechatnikov [11] found low T3 and T4 with high TSH concentrations in patients with COPD, reflects the nonthyroidal illness syndrome. Turkay Akbas et al [12] were also found low FT3 and TSH levels in critically ill COPD patients but it varies according to gender. Female patients had lower FT3 than males and increased when they recovered from critical illness. We also found that in exacerbation phase the mean FT3 and TSH values were lower as compared to stable and healthy controls but did not vary according to gender. These findings suggest that in A/E phases of COPD significant changes develop in neuroendocrine axis and hormone suppression vanishes with disease improvement. Dimopoulou et al [7] found that all patients had normal values for resting thyroid hormones however, in severe COPD; a certain degree of thyroid dysfunction was evident. Hugli et al [13] reported normal levels of thyroid hormones in 11 clinically stable COPD patients with normal weight. Gow et al [9] investigated thyroid function in 20 patients with exacerbation, having severe COPD (highest FEV1 40% of predicted). They did not find any correlation between arterial blood gas measurement and thyroid hormone concentrations in patients with COPD. Okutan et al [14] compared 32 COPD patients with 15 controls in which they found PFT and pO₂ significantly lower and T3 levels to be higher .In this study, the findings were dissimilar with respect to FT3 but significantly low pO₂ and PFT in the stable as well as among A/E COPD patients. They found a positive association in between pCO₂ and FT3 while all other values were negatively correlated with FT3. In our study, in between PFT and TFT there was no correlation in between PFT and TFT while all other values were negatively correlated with FT3. In our study, in between PFT and TFT there was no correlation in between PFT and TFT while all other values were negatively correlated with FT3. In our study, in between PFT and TFT there was no correlation in between PFT and TFT while all other values were negatively correlated with FT3. In our study, in between PFT and TFT there was no correlation in between PFT and TFT while all other values were negatively correlated with FT3. In our study, in between PFT and TFT there was no correlation in between PFT and TFT while all other values were negatively correlated with FT3. In our study, in between PFT and TFT there was no correlation in between PFT and TFT while all other values were negatively correlated with FT3.
Thyroid hormone levels in patients with COPD. Funda COSKUN et al [16] reported no significant difference in TSH and FT3 between group 1(COPD) and 2(Healthy controls) but significant difference on the basis of severity of disease. Systemic response to chronic disease in COPD patients might cause a hormonal imbalance which in turn affects the severity of the disease [16].

So far there is no evidence that thyroid function is consistently altered in COPD except in a subgroup of patients having severe hypoxemia. We tried to find out the comparative assessment in between the stable and A/E COPD groups with age matched healthy controls. As thyroid hormone constitutes their role in the metabolic process. Increased respiratory drive in COPD patients may alter thyroid function. Our study suggests that it impacts its effect in the form of the Non thyroidal illness syndrome, yet it is not known that whether illness syndrome is a favorable compensatory mechanism to offset catabolism and protein breakdown or it is an unfavorable adaptation with resultant biochemical hypothyroidism [6]. Furthermore extensive studies are required to identify underlying mechanism and consequences of thyroid dysfunction and its role in supplementation. The limitation of this study is, it’s an analytical observational study with lesser sample size and hence a follow up study during the recovery phase from exacerbation may be required to substantiate the findings.

In conclusion, mean level of FT3 was significantly lower among A/E COPD. Hypoxemia and hypercapnia did not correlate with Thyroid function test .We suggest that among A/E group due to having critical illness, the existence of Non-thyroidal illness syndrome prevalent as compared to stable COPD and healthy controls.

References


Correspondence to:

Madhuri Gupta
Department of Biochemistry,
SMS Medical College and Hospital
Jaipur, India.